

Falardeau, P., Champagne, P., Poyet, P., Hariton, C., & Dupont, É. (2001). Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. *Seminars in oncology*, 28(6), 620-625.

Fayette, J., Soria, J. C., & Armand, J. P. (2005). Use of angiogenesis inhibitors in tumour treatment. *European Journal of Cancer*, 41(8), 1109-1116.

Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International journal of cancer*, 127(12), 2893-2917.

Ferrara, N. (1997). The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: *Tumour Angiogenesis*, pp. 185–199, Bicknell, R. L. and Claire, E. (eds.) Oxford University Press, Oxford.

Ferrara, N. (1999). Molecular and biological properties of vascular endothelial growth factor. *Journal of Molecular Medicine*, 77(7), 527-543.

Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T. N., Peers, D., ... & Schwall, R. H. (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. *Nature medicine*, 4(3), 336-340.

Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. *Nature medicine*, 9(6), 669-676.

Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nature reviews Drug discovery*, 3(5), 391-400.

Fife, K., Phillips, R. H., Howard, M. R., Bower, M., & Gracie, F. (1998). Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. *International journal of STD & AIDS*, 9(12), 751-755.